THE ONLY BIOLOGIC APPROVED IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS

INDICATION

DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

DUPIXENT is the first and only dual inhibitor of IL-4 and IL-13 signaling approved in CRSwNP1

  • a In a prespecified subanalysis of patients self-identified with comorbid asthma.
INCS, intranasal corticosteroids; LMK-CT, Lund-Mackay computed tomography; SNOT-22, 22-item Sino-Nasal Outcome Test; SCS, systemic corticosteroid.
    Reference:
  1. DUPIXENT Prescribing Information.